Navigation Links
SHUR/Mark® PLUS Combo

ProductsSHUR/Mark® PLUS Combo
Company Triangle Biomedical Sciences, Inc.
Item SHUR/Mark® PLUS Combo
Features 
  • Each instrument includes an internal computer with Windows® operating system, color LCD membrane touch screen, keyboard, bar code reader, 6 position dispensing hopper, collection hopper, formatting & networking software and Ethernet connectivity
  • Includes a 6 position-dispensing hopper to allow for various colors
  • Using a proprietary non-contact ink-jet technology, SHUR/Mark® PLUS eliminates the need for earlier generation mechanical hopper dispensing mechanisms and mechanical x/y/z plotter hardware
  • A dependable conveyor system transports cassettes and slides across a fixed position ink jet-head
  • SHUR/Mark® PLUS completes the data integrity loop by further minimizing user interaction
  • Through built-in serial and Ethernet ports, data from an LIS (Laboratory Information System) can easily be sent to SHUR/Mark® PLUS
  • Ethernet connectivity offers remote diagnostic capabilities
  • Printing with SHUR/Mark® PLUS offers all of the advantages of Windows software such as the range of print sizes, italics, different font types, bold or underlined characters, the ability to prints images (logos), etc.,
  • Bar codes can be printed on cassettes and slides
Description Improving on the technology that the world has come to expect from the original SHUR/Mark® Cassette and Slide Labelers, SHUR/Mark® PLUS offers many added enhancements.
Info Triangle Biomedical Sciences, Inc.
Customer Service: 919.384.9393
Web site: http://www.trianglebiomedical.com/index.html

Related medicine products :

1. SHUR/Mark® PLUS Cassette Labeler
2. HRR/Amsler Book Combo
3. Akahoshi Combo Prechop (temporal approach)
4. ComboMap Pressure and Flow System
5. Clearview hCG Combo
6. Clearview hCG Combo w/ Reference Line
7. Aptima Combo 2® Assay
8. BioStar Acceava hCG Combo
9. hCG Combo Urine/Serum - Rapid Test
10. Dengue IgG and IgM Combo - Rapid Test
11. Plateletworks Combo-25 Kit
Breaking Medicine Technology:Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 1CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 2CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 3National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 1National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 2National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 3National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 4Accera Announces Peer Reviewed Publication of the Results of its 90 Day Clinical Study of AC 1202 28Axona 28TM 29 29 in Mild to Moderate Alzheimers 13530 1Accera Announces Peer Reviewed Publication of the Results of its 90 Day Clinical Study of AC 1202 28Axona 28TM 29 29 in Mild to Moderate Alzheimers 13530 2Accera Announces Peer Reviewed Publication of the Results of its 90 Day Clinical Study of AC 1202 28Axona 28TM 29 29 in Mild to Moderate Alzheimers 13530 3